Erratum: Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: A fixed-effects meta-analysis with predefined heterogeneity quality criteria (PLoS ONE (2014) 9, 6 (e99276) DOI:10.1371/journal.pone.0099276);Twice- Or once-daily dosing of novel oral anticoagulants for stroke prevention: A fixed-effects meta-analysis with predefined heterogeneity quality criteria

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Clemens, Andreas ^a,b   Noack, Herbert ^b   Brueckmann, Martina ^b,c   Lip, Gregory Y H ^d  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; EMBOLISM; HAZARD RATIO; HEALTH SERVICE; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER METABOLISM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTEMIC EMBOLISM; DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PREMEDICATION; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PREMEDICATION; STROKE; TREATMENT OUTCOME;

EID: 84902665694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109437     Document Type: Erratum

References (24)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, et al Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators (2010) Newly identified events in the RE-LY trial. N Engl J Med 363: 1875-1876.
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992.
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al; ROCKET AF Investigators(2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891.
5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, et al ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369: 2093-2104.
6. Ruff ChT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, et al. (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383: 955-962.
7. Jackson D (2006) The power of the standard test for the presence of heterogeneity in meta-analysis. Stat Med 25: 2688-2699.
8. Deeks JJ, Higgins JPT, Altman DG (2008) Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley. pp. 243-296.
9. Higgins J, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
10. Hardy RJ, Thompson SG (1998) Detecting and describing heterogeneity in meta-analysis. Stat Med 17: 841-856. (Pubitemid 28185164)
11. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analysis. BMJ 327: 557-560.
12. Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50: 683-691. (Pubitemid 27341818)
13. Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326: 472.
14. Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, et al. (2012) Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin 28: 195-201.
15. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, et al. (2010) Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103: 1116-1127.
16. Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53: 1-16.
17. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, et al. (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100: 453-461.
18. Frost C, Nepal S, Wang J, Schuster A, Byon W, et al. (2013) Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76: 776-786.
19. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, et al. (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50: 743-753.
20. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, et al. (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation- Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160: 635-641.
21. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, et al ARISTOTLE Investigators (2010) Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale [Erratum in: Am Heart J 2010; 159: 1162]. Am Heart J 159: 331-339.
22. Song X, Sander SD, Varker H, Amin A (2012) Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs 12: 245-253.
23. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23: 1296-310. (Pubitemid 32804122)
24. Francis KM, Siu K, Yu C, Alvrtsyan H, Rao Y, et al. (2012) Persistence among patients with non-valvular atrial fibrillation beginning dabigatran or warfarin. Blood (ASH Annual Meeting Abstracts) 120: 365.